Phase 3 N=407 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenic Purpura
Primary: Adverse Events — 162; 215 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=21 A Study to Evaluate GSK1325760A - a Long-Term Extension Study
Pulmonary Arterial Hypertension · Hypertension, Pulmonary
Primary: Number of Participants With Any Adverse Event — 21 participants
Phase 3 N=373 Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.
Pneumococcal Disease · 13-valent Pneumococcal Vaccine
Primary: Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the…
Phase 3 N=381 NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
Glabellar Frown Lines
Primary: Responder by Independent Rater's Assessment at Maximum Frown at Week 4 — 267; 89 participants
Phase 3 N=238 Clobazam in Patients With Lennox-Gastaut Syndrome
Epilepsy · Epilepsy, Generalized · Seizures
Primary: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). — 41.2; 49.4; 68.3; 12.1 Percent Reduction — p=0.0120
Phase 3 N=262 Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
13-valent Pneumococcal Vaccine · Immunization · Safety
Primary: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine…
Phase 3 N=1,071 Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
Essential Hypertension
Primary: Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure. — -42.5; -44.0; -37.1 mmHg — p=<0.001
Phase 3 N=1,715 Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension
Hypertension
Primary: Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis) — -28.9; -15.9; -15.1 mmHg…
Phase 3 N=609 Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
Essential Hypertension
Primary: Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure — -35.1; -29.5; -37.8; -32.8 mmHg — p=<0.001
Phase 3 N=300 A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India
Meningococcal Infection · Meningitis
Primary: Number of Participants With Vaccine Antibody Titers at ≥ 8 Before and After Menactra Vaccination — 17; 27; 23; 95 Participants
Phase 3 N=379 Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96 — 76.4; 83.2 Percentage of…
Phase 3 N=201 Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)
Hepatitis C, Chronic
Primary: Sustained Virologic Response (SVR) Rate in Full Analysis Set (FAS) Population. — 20.9; 64.2 Percentage of Participants
Phase 3 N=86 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
Short Bowel Syndrome
Primary: Responder — 27; 13 subjects — p=0.002
Phase 3 N=313 Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 26 — -1.15; -0.40 Percent of glycosylated hemoglobin
Phase 3 N=133 Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 12 — -0.15; -0.76 Percent — p=< 0.0001